Brukinsa

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

AbbVie files to move Venclexta combo into the CLL front line

AbbVie has filed for FDA approval of a new front-line therapy for chronic lymphocytic leukaemia that it thinks could be 'practice changing."

News

NICE backs new drugs for Crohn's disease, lymphoma

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

News

AZ claims EU approval for new Calquence regimens in CLL

AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.

News

Micrograph showing a small B-cell lymphoma compatible with follicular lymphoma

BeiGene breaks new ground for BTK drugs in blood cancers

BeiGene’s BTK inhibitor Brukinsa has become the first drug in the class to be approved in the US for follicular lymphoma, giving it the broadest label among its rivals.

News

BeiGene's Brukinsa FDA approved for CLL/SLL

Beijing-based pharma, BeiGene’s

FDA clears first all-oral combo for first-line CLL treatment

AbbVie files to move Venclexta combo into the CLL front line

NICE backs new drugs for Crohn's disease, lymphoma

AZ claims EU approval for new Calquence regimens in CLL

BeiGene breaks new ground for BTK drugs in blood cancers

BeiGene's Brukinsa FDA approved for CLL/SLL

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Brukinsa

Editor's Picks